Riabal (prifinia bromide) syrup 7.5 mg/5 ml. 60 ml. vial

$19.50

Manufacturer: Japan

Purpose: Blocks acetylcholine, treats muscle spasms in GI tract.

Out of stock

SKU: MED60995 Categories: , ,

Description

Riabal (prifinia bromide) syrup 7.5 mg/5 ml. 60 ml. vial

Ingredients

Active ingredient: Prifinia bromide
Other ingredients: [List other ingredients here]

Dosage

Adults: The usual dose is 7.5 mg (5 ml) 3 times a day.
Children: Dosage is based on weight. Consult a healthcare provider for the appropriate dose.

Indications

Riabal syrup is indicated for the treatment of gastrointestinal spasms and irritable bowel syndrome.

Contraindications

Do not use Riabal syrup if you are allergic to prifinia bromide or any other ingredients in the product. Consult your doctor if you have certain medical conditions before taking this medication.

Directions

Shake well before use. Take Riabal syrup as directed by your healthcare provider. Do not exceed the recommended dose.

Scientific Evidence

Studies have shown that prifinia bromide, the active ingredient in Riabal syrup, effectively reduces gastrointestinal spasms by blocking acetylcholine receptors in the smooth muscle of the digestive tract. This action leads to decreased muscle contractions, providing relief from symptoms associated with irritable bowel syndrome.

Additional Information

Riabal syrup is well-tolerated by most patients; however, common side effects may include dry mouth, blurred vision, and constipation. If you experience any severe side effects, discontinue use and consult your healthcare provider.

Pharmacological Effects: Prifinia bromide acts as a competitive antagonist of acetylcholine at muscarinic receptors in the gastrointestinal tract, leading to decreased smooth muscle contractions and spasmolytic effects.

Clinical Trials: A randomized controlled trial published in the Journal of Gastroenterology and Hepatology demonstrated the efficacy of prifinia bromide in reducing abdominal pain and improving stool consistency in patients with irritable bowel syndrome compared to a placebo group.